

Two seminal events in one! An unprecedented gathering to review the latest research in metabolic surgery and to develop new guidelines for the development of a modern, multi-modality approach to the care of type 2 diabetes.



3RD WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

The World Congress is a comprehensive, multidisciplinary

forum where leading international experts will conduct

a critical review and discussion of the latest research

findings on metabolic/bariatric surgery and novel



2ND DIABETES SURGERY SUMMIT DSS-II

The aim of the 2nd Diabetes Surgery Summit -DSS-II- is to assist leading diabetes organizations in the development of guidelines that integrate medical and surgical therapies in a rational treatment algorithm for T2DM.

September 28-30, 2015 | London, UK

www.wcitt2d.org

interventional therapies for type 2 diabetes.



DSS PARTNERS













ZING'S

LONDON

WELCOME TO THE 3RD WORLD CONGRESS

Dear Colleagues and Friends,

A number of gastrointestinal operations referred to as bariatric/metabolic surgery can cause dramatic improvement or even long-term remission of type 2 diabetes, a disease otherwise considered chronic and irreversible. Over the past decade, clinical and experimental research has shown that such powerful anti-diabetes effect results from changes in various aspects of gastrointestinal physiology, revealing a crucial and previously underappreciated role of the gut in glucose metabolism.



This new knowledge challenges traditional paradigms of disease and may provide clues for the discovery of the yet elusive causes of this illness.

Despite surgical treatment of type 2 diabetes is now supported by evidence from randomized clinical trials, significant barriers still prevent access to surgery for those who need it. Furthermore, the exact mechanisms by which surgery controls diabetes are not completely understood; advancing this knowledge may reveal new targets for future, less invasive interventional therapies and novel pharmaceuticals.

To address the challenges and seize the opportunities that surgery offers to diabetes care and research, we established the World Congress on Interventional Therapies for Type 2 Diabetes, an international forum where a stellar Faculty of clinicians, scientists and policy makers discuss available evidence on the use and study of bariatric/metabolic surgery and new device-based intervention. The overarching aim of the congress is to craft an agenda of research priorities and health policy initiatives.

The previous two editions of the world congress, held in New York in 2008 and 2011 attracted participants from nearly 65 countries, establishing this meeting as the most prestigious multidisciplinary gathering entirely dedicated to the emerging field of diabetes surgery. The 3rd Edition of the World Congress will be held in London, UK, on September 28-30, 2015, jointly with the 2nd Diabetes Surgery Summit (DSS-II), an influential consensus conference aimed at the development of guidelines and recommendations for a modern, multimodality approach to the care of diabetes.

Draft DSS guidelines will be presented during dedicated plenary sessions of the world congress and open to public input by Faculty members and the audience at large. On the last day of the event, the DSS delegates will use such input to refine and approve a final DSS document that informs clinicians about the role of surgery in diabetes care. Attendance of this truly historical event provides a unique opportunity to get abreast of the science behind metabolic surgery and to participate in initiatives that will expand the horizons of diabetes care and research for years to come.

On behalf of the organizing committee and myself, I look forward to welcoming you to London for this exciting and memorable event.

ranceles Juli

Prof. Francesco Rubino, MD Director, World Congress Chair, Bariatric and Metabolic Surgery King's College London London, UK

WELCOME TO DSS-II

CO-DIRECTORS



Jeaner Lulius

Francesco Rubino King's College London London, UK



Phil Schauer Cleveland Clinic Cleveland, USA



David Cummings University of Washington Seattle, USA



Jukaplan

Lee Kaplan Harvard Medical School Boston, USA

ORGANISING COMMITTEE

George Alberti, UK Stephanie Amiel, UK Ricardo Cohen, Brazil Paul Zimmet, Australia John Dixon, Australia Carel le Roux, Ireland Geltrude Mingrone, Italy Linong Ji, China Robert Ratner, USA Shaukat Sadikot, India Bruce Wolfe, USA Dear Colleagues and Friends,

It is our pleasure to invite you to attend the 2nd Diabetes Surgery Summit (DSS-II), September 28-30, 2015 in London, England, one of the most important scientific events of 2015.

A significant body of evidence has accumulated, including several randomized clinical trials, demonstrating that bariatric/metabolic surgery can achieve excellent control of hyperglycemia and reduce cardiometabolic risk in patients with diabetes. Research on the mechanisms of action of these procedures has also revealed a critical role of the gastrointestinal (GI) tract in glucose metabolism, providing a biological rationale for the use of GI-based interventions in the treatment of T2DM.

Despite increasing recognition of the efficacy, safety and cost-effectiveness of metabolic surgery, this potentially life-saving approach has not yet been fully integrated in the treatment algorithm of type 2 diabetes. On the other hand, the practice of traditional bariatric surgery is entirely shaped around obesity and weight reduction; as such, it is not coherent with the principles and standards of diabetes care. There are also no strategies yet for the integration of complementary pharmaceutical and surgical therapies to optimize outcomes of diabetes management.

The aim of the 2nd Diabetes Surgery Summit -DSS-II- is to assist leading diabetes organizations in the development of guidelines that integrate medical and surgical therapies in a rational treatment algorithm for T2DM. Specific goals include providing guidance for the selection of surgical candidates and for the use of diabetes-specific measures in the preoperative workup and follow-up of patients. The DSS-II also aims at designing an agenda of research priorities and health policy initiatives that ensure equitable access to surgery when indicated.

Through a rigorous consensus development process based on current, high quality evidence, a multidisciplinary group of international authorities in the field of endocrinology, internal medicine, nutrition and surgery, including official representatives of major diabetes organizations, will develop evidence-based guidelines and recommendations.

A draft with proposed guidelines and their supporting evidence will then be presented during dedicated plenary sessions of the 3rd World Congress on Interventional Therapies of Type 2 Diabetes in London, UK on Sept 28-30, 2015. There, they will be critically discussed by other thought leaders in the field and open to input by the audience at large to measure the degree of agreement for each proposal. On the last day of the congress, the expert group will define the final consensus document that is designed to inform general practitioners, physicians, surgeons and policy makers.

On behalf of the organizing committee, we cordially invite you to attend the DSS-II and 3rd World Congress and actively participate in a seminal event that will lay the foundation of modern, multimodality care of diabetes.

WHO SHOULD ATTEND?

This Congress is designed for professionals in the fields of endocrinology, diabetes, bariatric/ metabolic, surgery, cardiology, epidemiology, gastroenterology, internal medicine, family medicine, pharmacology nutrition, basic science, and public health, as well as allied health professionals, policy makers, and scientists from pharmaceutical and medical device industry.

REGISTER IN ADVANCE TO SAVE ON FEES WWW.WCDITT2D.ORG

SPECIFIC THEMES

Development of new recommendations/ guidelines for integrated, multimodality treatment of type 2 diabetes - DSS-II

- Epidemiology and economic impact of diabetes
- Impact of metabolic surgery on cardiovascular risk
- Role of integrated surgical and medical approaches for diabetes (multimodality therapies)
- Mechanisms of action of bariatric and metabolic surgery
- Novel technologies and gastrointestinal devices for diabetes
- Cost effectiveness of surgery as a treatment of diabetes
- Addressing barriers to proper health care utilization: beyond stigma, misconceptions and discrimination
- Developing adequate health policies for improved, equitable access to surgery
- Role of the gastrointestinal tract in glucose metabolism
- Challenging conventional paradigms of diabetes and obesity: a debate by leading scientists in the field

FACULTY (UPDATED AS OF JUNE 2015)

Ted Adams, USA Nizar Albache*, USA George Alberti*, UK Stephanie Amiel*, UK Simon Aylwin, UK **Rachel Batterham***, UK Shlomo Ben Haim, UK **Richard Bergman**, USA **Deepak Bhatt*,** USA Steve Bloom, UK Stefan Bornstein, UK Camilo Boza*, Chile Stacy Brethauer, USA Lena Carlsson. Sweden David Cavan, Belgium William Cefalu*, USA Avril Chang, UK Alan D. Cherrington. USA Pradeep Chowbey, India Karine Clement. France Ricardo Cohen*. Brazil Anita Courcoulas*, USA David Cummings *, USA Stephano Del Prato*, Italy Sean Dinneen*, Ireland John Dixon*, Australia Daniel Drucker, Canada **Robert Eckel***, USA Ele Ferrannini*, *Italy* Nick Finer, UK **Paola Fioretto***, *Italy* Gema Frühbeck*, Spain Susana Fuentes, Argentina Michel Gagner*, Canada Manoel Galvao-Neto. Brazil Alfredo Genco, *Italy* Jonathan Grant, UK

Richard W. Grant*. USA Jan Willem Greve, The Netherlands Fiona Gribble, UK William Herman*, USA Add Miguel Herrera, Mexico Jacques Himpens, Belgium Kelvin Higa, USA Michael Hirst, UK Jens Juls Holst, Denmark Thomas H. Inge, USA Sayeed Ikramuddin*, USA **Des Johnston*,** UK Peter Jones, UK Lee Kaplan*, USA Add Filip Knop, Denmark Sangeeta Kashyap*, USA **Tracey Kelly*,** UK John Kirwan. USA **Tomasz Klupa*,** *Poland* Judith Korner*, USA Blandine Laferrere*. USA Tony Lam, Canada Antonio M. Lacy, Spain Mike Lean, UK Carel Le Roux*, Ireland Harold Lebovitz*, USA Randy Levinson**, USA W.J. Lee*, Taiwan Ji Linong*, China Josemberg Martins Campos, Brazil Barbara McGowan, UK Jeffrey Mechanick*, USA **Geltrude Mingrone*,** *Italy* John Morton*, USA David Nathan*. USA Pablo Omelanczuk, Argentina Simon O'Neill, UK

Ameet Patel, UK Mary Elizabeth Patti, USA Francois Pattou, France Mark Peakman. UK Shanta Persaud, UK Jonathan Pinkney, UK Walter Pories*, USA Almino Ramos, Brazil **Robert Ratner***, USA Gerry Rayman*, UK Francesco Rubino*, UK Shaukat Sadikot*, India Marzieh Salehi, USA Philip Schauer*, USA Andre Scheen*, Belgium Randy Seeley, USA Scott Alan Shikora, USA Nicholas Stylopoulos. USA Harvey Sugerman*, USA Gaspar Taroncher**, USA Luiz Turrati. Brazil Luc Van Gaal*, Belgium Josep Vidal*, Spain **Richard Welbourn,** UK **Jianping Weng***, China Anthony Wierzbicki, UK Bruce Wolfe*, USA Paul Zimmet*, Australia



Monday, September 28, 2015

TIME	SESSION
08:00-08:30	Opening Ceremony
08:30-09:00	World Congress and DSS: Rationale and Methods
08:30-08:45	World Congress and Diabetes Surgery Summit: Introduction Francesco Rubino, UK
08:45-09:00	DSS-II: Appraisal of Evidence and Consensus Development Gaspar Taroncher-Oldenburg, USA
09:00-10:00	WCITT2D Session 1 – Clinical Track Diabetes Care: Epidemiology and Limitations of Conventional Treatments Chairman: George Alberti, UK
09:00-09:20	Epidemiology of Diabetes- Status of a Pandemic Paul Zimmet, Australia
09:20-09:40	Cardio-metabolic Risk in Type-2 Diabetes Robert Eckel, USA
09:40-10:00	Reducing CVD in T2DM: Limitations of Conventional Treatments David Nathan, USA
10:00-12:10	WCITT2D/DSS-II: Joint Session Clinical Outcomes of Bariatric/Metabolic Surgery: Part 1 Chairmen: Stephanie Amiel, UK; Harold Lebovitz, USA
10:00-10:20	Durability of Diabetes Control, Reduction of Micro- and Macro-vascular Complications of Diabetes in the SOS Study Lena Carlsson, Sweden
10:20-10:40	Reduction of CV Disease and Death after Bariatric/Metabolic Surgery Ted Adams, USA
10:40-11:00	Coffee Break
11:00-11:30	Overview of RCTs Comparing Surgery vs Medical Therapy for T2DM Philip Schauer, USA
11:30-12:10	Panel Discussion: Short- and Long-Term Benefits of Bariatric/ Metabolic Surgery Panel: Robert Ratner, USA; John Dixon, Australia; Sayeed Ikramuddin, USA; Anita Courcoulas, USA; Geltrude Mingrone, USA; Des Johnston, UK
12:10-12:30	Short- and Long-term Safety of Metabolic/Bariatric Surgery Bruce Wolfe, USA

Monday, September 28, 2015

TIME	SESSION
12:30-13:40	WCITT2D/DSS-II: Joint Session Controversial Issues in Bariatric/Metabolic Surgery Chairmen: TBA
12:30-12:50	Surgery for Diabetes in Patients with BMI < 35Kg/m2 David Cummings, USA
12:50-13:10	Outcomes of Bariatric/Metabolic Surgery in Adolescents: Clinical Evidence Thomas Inge, USA
13:10-13:40	Panel Discussion: Adolescents and the Issue of BMI Panel: Paola Fioretto, Italy; John Meckanick, USA; Richard W. Grant, USA; A. Desai, USA; Stephanie Amiel, UK; Nick Finer, UK
13:30-14:40	Lunch Break
14:40-16:10	WCITT2D Session 2 - Research-Track Mechanisms of Action of Metabolic Surgery – 1 Chairmen: Jianping Weng, China; David Cummings, USA
14:40-15:00	What Does the Effectiveness of Surgery Tell us About the Physiology and Pathophysiology of Glucose Homeostasis Richard Bergman, USA
15:00-15:20	Effects of Different GI Procedures on Insulin Sensitivity Ele Ferrannini, Italy
15:20-15:40	Effects of Different GI Procedures on Beta-cell Function and Mass Sangeeta Kashyap, USA
15:40-16:10	Panel Discussion: Geltrude Mingrone, Italy; Blandine Laferrere, USA; Peter Jones, UK; Shanta Persaud, UK; William Cefalu', USA; Stephanie Amiel, UK
16:10-16:25	Coffee Break
16:25-17:15	WCITT2D Session 3: Clinical Track Novel Operations and Device-Based Interventions Chairmen: Stephan Bornstein, UK; John Morton, USA
16:25-16:40	Novel Surgical Procedures: DJB, IT, SADI: State of the Art Ricardo Cohen, Brazil
16:40-16:55	Baloon/Overview and Techniques Alfredo Genco, Italy. TBA
16:55-17:10	Endoluminal Barrier Jan Willem Greve, The Netherlands
17:10-17:25	Endoscopic Duodenal Mucosal Ablation Alan D. Cherrington, USA

Monday, September 28, 2015

ТІМЕ	SESSION
17:25-17:40	Vagal Stimulation Scott Alan Shikora, USA
17:40-17:55	Gastric Electric Stimulation Harold Lebovitz, USA
17:55-18:30	Interventional Diabetology: Between Present and Future Ameet Patel, UK; Shlomo Ben-Heim, UK; Manoel Galvao-Neto, Brazil; Lee Kaplan, USA; Tomasz Klupa, Poland; Jonathan Pinkney, UK; Stacy Brethauer, USA
18:30-20:00	Satellite Symposium – Not included in the main event CME/CPD
19:30-20:30	WCITT2D 2015 Cocktails and Poster Session Chairmen: Barbara McGowan, UK; John Dixon, Australia
20:30	Welcome Reception and Dinner

ТІМЕ	SESSION
07:30-10:00	WCITT2D 2015: Symposium 1 The Gut in the Physiology and Pathophysiology of Metabolic Diseases Chairmen: Steve Bloom, UK; Fiona Gribble, UK
07:30-07:50	The Gut as an Endocrine Organ – Role in the Regulation of Food Intake and Body Weight Steve Bloom, UK
07:50-08:10	The Gut as an Endocrine Organ – Role in the Regulation of Glucose Homeostasis Daniel Drucker, Canada
08:10-08:30	Bile Acids and Metabolic Regulation Carel le Roux, Ireland
08:30-08:50	Intestinal Nutrient Sensing and Endoluminal Leptin Signaling Tony Lam, Canada
08:50-09:10	Gut Microbiota and Inflammation Karine Clement, France
09:10-09:30	The Anti-incretin Theory: The Role of the Gut in the Physiology and Pathophysiology of Glucose Homeostasis Francesco Rubino, UK
09:30-10:00	Panel Discussion: The Gut in Obesity and Diabetes Panel: David Nathan, USA; Rachel Batterham, UK; Ele Ferrannini, Italy; Richard Bergman, USA; Randy Seeley, USA; Mark Peakman, UK

SESSION	
Coffee Break	
WCITT2D Session 4: Research Track Mechanisms of Action of Metabolic Surgery Chairmen: Ele Ferrannini, Italy; Richard Be	
The Physiology of Metabolic Surgery Lee Kaplan, USA	
Distribution and Regulation of Entero-endo Fiona Gribble, UK	crine Cells
Effects of GI Surgery on Gut Hormones Jens Juls Holst, Denmark	
Effects of GI Surgery on Bile Acids and Micr Randy Seeley, USA	robiota
Effects of GI Surgery on Intestinal Glucose Nicholas Stylopolous, USA	Metabolism and Absorption
Postprandial Hypoglycemia after Gastic By Possible Treatment Mary Elizabeth Patti, USA	pass Surgery: Mechanistic Implications and
Panel Discussion Daniel Drucker, Canada; Carel le Roux, Irel Josep Vidal, Spain ; Tony Lam, Canada	and; Judith Korner, USA;
Lunch Break	Satellite Symposium – Not included in the main event CME/CPD
WCITT2D 2015: Clinical Track Ethnic Considerations and Regional Challer Chairmen: Jianpeng Weng, China; Pradeep	•
The Characteristics of Diabetes in East Asia Ji Linong, China	an Populations
The Characteristics of Diabetes in South As Shaukat Sadikot, India	sian Populations
Diabetes in the Middle East Nizar Albache, USA	
Metabolic Surgery in Asia and Middle East W.J. Lee, Taiwan	
	Coffee BreakWCITT2D Session 4: Research Track Mechanisms of Action of Metabolic Surgery Chairmen: Ele Ferrannini, Italy; Richard BerThe Physiology of Metabolic Surgery Lee Kaplan, USADistribution and Regulation of Entero-endor Fiona Gribble, UKEffects of GI Surgery on Gut Hormones Jens Juls Holst, DenmarkEffects of GI Surgery on Bile Acids and Micro Randy Seeley, USAEffects of GI Surgery on Intestinal Glucose Nicholas Stylopolous, USAPostprandial Hypoglycemia after Gastic By Possible Treatment Mary Elizabeth Patti, USAPanel Discussion Daniel Drucker, Canada; Carel Le Roux, Irel Josep Vidal, Spain ; Tony Lam, CanadaLunch BreakWCITT2D 2015: Clinical Track Ethnic Considerations and Regional Challe Chairmen: Jianpeng Weng, China; Pradeep The Characteristics of Diabetes in East Asia Ji Linong, ChinaThe Characteristics of Diabetes in South As Shaukat Sadikot, IndiaDiabetes in the Middle East Nizar Albache, USAMetabolic Surgery in Asia and Middle East

ТІМЕ	SESSION		
15:00-16:30	Satellite Symposium – Not included in the main event CME/CPD		
16:30-16:45	Coffee Break		
16:45-19:30	WCITT2D 2015 – Breakout Sessions		
	Clinical Outcomes of Metabolic/Diabetes Surgery	The Science Behind Metabolic Surgery	Diabetes Surgery And Health Care Policies
	Chairmen: Carel Le Roux, Ireland; Simon Aylwin, UK	The Mechanisms of Action of Metabolic Surgery Chairmen: Rachel Batterham, UK; John Kirwan, USA	Cost effectiveness and Coverage of Bariatric/ Metabolic Surgery Chairmen: William Herman, USA; Paul Zimmet, Australia
	16:45-17:00 A National Registry of Bariatric/Metabolic Surgery: The UK Experience Richard Welbourn, UK	16:45-17:00 Potentiation of the Incretin Effect by GI Surgery Blandine Laferrere, USA	16:45-17:00 Effectiveness of Bariatric Surgery: What Policy Makers Should Know TBA
	17:00-17:15 Sleeve Gastrectomy Michel Gagner, Canada	17:00-17:15 Gastrointestinal Bypass Reduces Physiologic Anti-incretin Mechanisms Geltrude Mingrone, Italy	17:00-17:20 Review of Cost- Effectiveness of Bariatric/ Metabolic Surgery TBA
	17:15-17:30 RYGB Kelvin Higa, USA	17:15-17:30 GI Surgery: Effects on Glucose Absorption Francois Pattou, France	17:20-17:40 Coverage of Bariatric/ Metabolic Surgery: Regional Differences John Dixon. Australia
	17:30-17:45 BPD and Duodenal Switch Jacques Himpens, Brussels	17:30-17:45 Do the Effects of Very Low Calorie Diet Mimic Those of RYGB? Judith Korner, USA	17:40-18:00 Coverage of Bariatric Surgery vs Other Elective Procedures: Does the Obesity Stigma Plays a Role?

TIME	SESSION		
	17:45-18:15 Debate: Sleeve Gastrectomy vs Gastric Bypass for the treatment of Diabetes: -The Case for Sleeve Gastrectomy Antonio M. Lacy, Spain -The Case for Gastric Bypass Walter Pories, USA	17:45-18:00 Role of the Duodenum in the Antidiabetic Effects of RYGB David Cummings, USA	18:00-19:30 Consensus Panel: Coverage of Bariatric/ Metabolic Surgery: What are The Barriers? What The Solutions? Development of Consensus for a White Paper Panelists: TBA
	18:15-18:30 Free paper on Clinical Outcomes of Metabolic/ Diabetes Surgery	18:00-18:15 Gastric Bypass Surgery: Effects on Glucose- Dependent and Glucose- Independent Mechanisms of Islet Hormone Secretion Marzieh Salehi, USA	
	18:30-18:45 Free paper on Clinical Outcomes of Metabolic/ Diabetes Surgery	18:30-18:40 Free Paper on Mechanisms of Surgery	
	18:45-19:30 Panel: Choosing the Appropriate Procedure for	18:40-18:50 Free paper on Mechanisms of Surgery	
	Diabetes Surgery: Gerry Rayman, UK; W.J. Lee, Taiwan; Camila Boza, Chile; Sean Dinneen, Ireland; Tomasz Klupa, Poland; Andre Scheen, Belgium; Antonio Torres, Spain; A. Chang; Jozep Vidal, Spain	18:50-19:30 Weight-dependent Effects or Changes in Gastrointestinal Physiology: Can the Argument be Settled? Richard Bergman, USA; Jens-Juls Holst, Denmark; Steve Bloom, UK; Fiona Gribble, UK;	
19:45-20:45	Satellite Symposium - Not i	ncluded in the main event Cl	ME/CPD
19:45-21:15	2 1	- "Metabolic Surgery: Science iety of Bariatric and Metabolic	

Wednesday, September 30, 2015

TIME	SESSION
08:00-09:40	WCITT2D/DSS-II- Joint Session Diabetes Surgery: Indications and Model of Care Chairmen: Robert Eckel, USA; Stephanie Amiel, UK DSS-II: Presentation of Recommendations and Guidelines for Diabetes Surgery
08:00-08:15	Definition of Diabetes-specific Goals and Success of Surgical Treatment Robert Ratner, USA
08:15-08:30	Preoperative Work-up in Diabetes Surgery Des Johnston, UK
08:30-08:45	Postoperative follow-up in Diabetes Surgery Jeffrey Mechanick, USA
08:45-09:00	Integrating Medical and Surgical Therapies to Optimize Outcomes Stefano Del Prato, Italy
09:00-09:15	DSS-II: Indications to Diabetes Surgery and New Agorithm for Diabetes Management George Alberti, UK
09:15-10:05	Panel Discussion and Voting Sessions with Experts and Audience: David Nathan, USA; Richard Grant, USA; William Herman, USA; John Morton, USA; Jonathan Pinkney, UK; Philip Schauer, USA; William Cefalu, USA; Deepak Bhatt, USA; Harold Lebovitz, USA
10:05-10:20	Coffee Break
10:20-12:50	WCITT2D –Session 6 –Policy Track Cost-effectiveness of Diabetes Surgery and Heath Care Policies Chairmen: Paul Zimmet, Australia; George Alberti, UK
10:20-10:35	The Cost of Diabetes William H. Herman, USA
10:35-10:50	Summary of Evidence for Diabetes Surgery Lee Kaplan, USA
10:50-11:10	Cost-effectiveness of Bariatric/Metabolic Surgery TBA
11:10-11:25	NICE Guidelines Rachel Batterham, UK
11:25-11:40	Diabetes Surgery and Health Care Policies: A Call to Action TBA
11:40-12:40	Panel Discussion: Barriers to Surgical Access: Costs or Stigma? Panelists: TBA

Wednesday, September 30, 2015

ТІМЕ	SESSION
12:40-14:00	WCITT2D/DSS-II: Joint Session Choice of Surgical Procedure Chairmen: Harvey Sugerman, USA; Walter Pories, USA
12:40-12:50	Risk/Benefit Profile of Gastric Banding John Dixon, USA
12:50-13:00	Risk/Benefit Profile of Biliopancreatic Diversion Geltrude Mingrone, Italy
13:00-13:10	Risk/Benefit Profile of Sleeve Gastrectomy Josep Vidal, Spain
13:10-13:20	Risk/Benefit Profile of Gastric Bypass Ricardo Cohen, Brazil
13:20-13:30	Presentation of DSS-II Recommendations / Guidelines: Anita Courcoulas, USA
13:30-14:00	Panel Discussion and Voting Session with Experts and Audience Michel Gagner, Canada; Antonio M. Lacy, Spain; Kelvin Higa, USA; Sayeed Ikramuddin, USA; Bruce Wolfe, USA; Jefrrey Mechanick, USA; John Morton, USA; Ameet Patel, UK
14:00-14:05	Closing Remarks / Adjourn
	DSS-Face-to-Face Meeting (only for DSS Delegates)
14:30-15:25	DSS Delegates Lunch and Coffee Break
15:35-15:35	Group Pictures
15:35-17:30	DSS Delegates Meeting Moderators: Randy Levinson, USA; Gaspar Taroncher-Oldenburg, USA

CONGRESS VENUE

Park Plaza Westminster Bridge Hotel

200 Westminster Bridge Road London, SE1 7UT UK

Tel: +44 844 415 6780 (Hotel Direct) Tel: +44 844 415 6790 Fax: +44 844 415 6791



The Park Plaza Westminster Bridge Hotel provides the most extensive modern meeting space in London and is situated in the thriving London South Bank area, within walking distance of the city's most iconic attractions, including Big Ben, the Houses of Parliament and the London Eye. This ideal central London location is 45 minutes from London Heathrow Airport and moments from Westminster and Waterloo Underground and Mainline stations.

DSS PARTNERS



ENDORSING SOCIETIES

